Jaykumar Thumar, MBBS, MD
Adjunct Assistant ProfessorAbout
Research
Publications
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, jco2401383. PMID: 39671534, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabinePerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
Clinical Trials
Current Trials
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
HIC ID2000026339RoleSub InvestigatorPrimary Completion Date06/30/2026Recruiting ParticipantsA Phase II Evaluation of Afatinib
HIC ID1503015437RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsGenderFemaleAgeUp to 18 years